Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Thyssen, Jacob P. [2 ]
Guttman-Yassky, Emma [3 ]
Bieber, Thomas [4 ]
Carrascosa, Jose Manuel [5 ]
Simpson, Eric [6 ]
Rosmarin, David [7 ]
Elmaraghy, Hany [8 ]
Meskimen, Eric [8 ]
Natalie, Chitra R. [8 ]
Liu, Zhuqing [8 ]
Xu, Chenjia [8 ]
Pierce, Evangeline [8 ]
Morgan-Cox, MaryAnn [8 ]
Silverberg, Jonathan, I [9 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR 97223 USA
[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ Hosp Bonn, Bonn, Germany
[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Tufts Univ, Sch Med, Boston, MA USA
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;
D O I：
10.1093/bjd/ljac140.018
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
322
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
    Alexis, Andrew F.
    Rendon, Marta
    Silverberg, Jonathan I.
    Pariser, David M.
    Lockshin, Benjamin
    Griffiths, Christopher E. M.
    Weisman, Jamie
    Wollenberg, Andreas
    Chen, Zhen
    Davis, John D.
    Li, Meng
    Eckert, Laurent
    Gadkari, Abhijit
    Shumel, Brad
    Rossi, Ana B.
    Graham, Neil M. H.
    Ardeleanu, Marius
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 804 - 813
  • [42] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [43] Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
    Pandya, Amit G.
    Ezzedine, Khaled
    Passeron, Thierry
    van Geel, Nanja
    Brown, Kurt
    Santos, Leandro
    Erskine, Lois
    Wagya, Kofi
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [44] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
    Youn, Sang Woong
    Jo, Seong Jin
    Park, Chul Jong
    Kim, Dong Hyun
    Shin, Bong Seok
    Jeong, Ki Heon
    Bang, Chul Hwan
    Cross, Nancy
    Thirlwell, Jackie
    Hoepken, Bengt
    JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1392 - 1403
  • [45] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Igawa, Ken
    CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
  • [46] Efficacy And Safety Of Nintedanib In Patients With Idiopathic Pulmonary Fibrosis: Results Of Two 52-Week, Phase Iii, Randomized, Placebo-Controlled Trials (inpulsis™)
    Richeldi, L.
    Du Bois, R.
    Raghu, G.
    Azuma, A.
    Brown, K. K.
    Costabel, U.
    Cottin, V.
    Flaherty, K.
    Inoue, Y.
    Kim, D.
    Kolb, M.
    Noble, P. W.
    Selman, M.
    Taniguchi, H.
    Brun, M.
    Girard, M.
    Schlenker-Herceg, R.
    Disse, B.
    Collard, H. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [47] EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: RESULTS OF TWO 52-WEEK, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIALS (INPULSIS™)
    Richeldi, L.
    Du Bois, R. M.
    Raghu, G.
    Azuma, A.
    Brown, K. K.
    Costabel, U.
    Cottin, V
    Flaherty, K. R.
    Inoue, Y.
    Kim, D. S.
    Kolb, M.
    Noble, P. W.
    Selman, M.
    Taniguchi, H.
    Brun, M.
    Girard, M.
    Schlenker-Herceg, R.
    Disse, B.
    Collard, H. R.
    RESPIROLOGY, 2014, 19 : 28 - 28
  • [48] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [49] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
    Clowse, Megan E. B.
    Wallace, Daniel J.
    Furie, Richard
    Petri, Michelle
    Pike, Marilyn
    Leszczynski, Piotr
    Neuwelt, C. Michael
    Hobbs, Kathryn
    Keiserman, Mauro
    Duca, Liliana
    Kalunian, Kenneth
    Bongardt, Sabine
    Stach, Christian
    Beaudot, Carolyn
    Kilgallen, Brian
    Galateanu, Catrinel
    Gordon, Caroline
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [50] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    Dermatology and Therapy, 2023, 13 : 595 - 608
12345